- Email: [email protected]
Contemporary Use of Monteleukast and Its Association With Depression in Asthma and Allergic Rhinitis Patients
October 2014, Vol 146, No. 4_MeetingAbstracts
Allergy and Airway | October 2014
Contemporary Use of Monteleukast and Its Association With Depression in Asthma and Allergic Rhinitis Patients Rajeev Narang, MBBS; Shreya Narang; Devina Narang; Grorge Udeani, DSc Corpus Christi Medical Center, Corpus Christi, TX
Chest. 2014;146(4_MeetingAbstracts):13A. doi:10.1378/chest.1987575
Abstract SESSION TITLE: Asthma Posters II SESSION TYPE: Original Investigation Poster PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM PURPOSE: Montelukast is an agent approved by FDA for the treatment of asthma and allergic rhinitis. Post marketing studies have suggested depressive symptoms and anxiety in some patient while on this agent. We designed a prospective study to access wheather or not patients on this agent developed depression.
METHODS: This was a prospective study with patient serving as their own control.This study was approved by the institutional Review Board. Forty patients were enrolled (11male and 29 female patients). The study population included patients with asthma and allergic rhinitis,with or without history of depression. Patients who had symptoms of depression in the previous six months were excluded. An initial HAM-D score was obtained by the prinicipal investigator on the first day of the study for each patient.Subsequently the patients were prescribed monteleukast 10 mg orally once daily. The patients were followed during office visits or via telephone calls. Patients had to have been on montelukast therapy for at least one month prior to evaluation for a subsequent HAM-D score. Paired Student's t-test was was used for statistical analysis with the Graphpad Prism software. RESULTS: Twenty-four patients sucessfully completed the study. Of these 24 cases, 5 were males and 19 were females.The mean age of patient population that completed the study was 53.62 ±17.83 (range18-84). Out of these 24 patients, 2 had a history of depression. The mean HAM-D score during the initial office visit for these patients was 4.29 ± 3.76. The mean HAM-D score upon completion of the study was 3.75 ± 3.82. The two-tailed P value equaled 0.566. Based on conventional criteria this difference was not considered to be statistically significant.
CONCLUSIONS: The above study demonstrates that montelukast is not asociated with symptoms depression,contrary to data from post marketing surveillance reports.
CLINICAL IMPLICATIONS: Montelukast is a safe drug for use in asthma patients,with and without symptoms of depression. DISCLOSURE: The following authors have nothing to disclose: Rajeev Narang, Shreya Narang, Devina Narang, Grorge Udeani No Product/Research Disclosure Information
Allergy and Airway | October 2014
Contemporary Use of Monteleukast and Its Association With Depression in Asthma and Allergic Rhinitis Patients Rajeev Narang, MBBS; Shreya Narang; Devina Narang; Grorge Udeani, DSc Corpus Christi Medical Center, Corpus Christi, TX
Chest. 2014;146(4_MeetingAbstracts):13A. doi:10.1378/chest.1987575
Abstract SESSION TITLE: Asthma Posters II SESSION TYPE: Original Investigation Poster PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM PURPOSE: Montelukast is an agent approved by FDA for the treatment of asthma and allergic rhinitis. Post marketing studies have suggested depressive symptoms and anxiety in some patient while on this agent. We designed a prospective study to access wheather or not patients on this agent developed depression.
METHODS: This was a prospective study with patient serving as their own control.This study was approved by the institutional Review Board. Forty patients were enrolled (11male and 29 female patients). The study population included patients with asthma and allergic rhinitis,with or without history of depression. Patients who had symptoms of depression in the previous six months were excluded. An initial HAM-D score was obtained by the prinicipal investigator on the first day of the study for each patient.Subsequently the patients were prescribed monteleukast 10 mg orally once daily. The patients were followed during office visits or via telephone calls. Patients had to have been on montelukast therapy for at least one month prior to evaluation for a subsequent HAM-D score. Paired Student's t-test was was used for statistical analysis with the Graphpad Prism software. RESULTS: Twenty-four patients sucessfully completed the study. Of these 24 cases, 5 were males and 19 were females.The mean age of patient population that completed the study was 53.62 ±17.83 (range18-84). Out of these 24 patients, 2 had a history of depression. The mean HAM-D score during the initial office visit for these patients was 4.29 ± 3.76. The mean HAM-D score upon completion of the study was 3.75 ± 3.82. The two-tailed P value equaled 0.566. Based on conventional criteria this difference was not considered to be statistically significant.
CONCLUSIONS: The above study demonstrates that montelukast is not asociated with symptoms depression,contrary to data from post marketing surveillance reports.
CLINICAL IMPLICATIONS: Montelukast is a safe drug for use in asthma patients,with and without symptoms of depression. DISCLOSURE: The following authors have nothing to disclose: Rajeev Narang, Shreya Narang, Devina Narang, Grorge Udeani No Product/Research Disclosure Information